Form 4: Prime Medicine Director Acquires Stock Options

Jeffrey D. Marrazzo, a director at Prime Medicine, Inc., acquired stock options for 800,000 shares of common stock on May 19, 2025.

Summary

• On May 19, 2025, Jeffrey D. Marrazzo, a director of Prime Medicine, Inc., was granted stock options to purchase 800,000 shares of the company's common stock.
• The exercise price of these options is $1.335 per share.
• 500,000 of the shares underlying the option will vest in 24 equal monthly installments starting May 19, 2025.
• The remaining 300,000 shares will vest in three equal installments based on the company meeting certain stock price performance criteria, contingent on Marrazzo's continued service.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. The vesting schedule based on both time and performance is also a positive sign.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards increasing the company's stock price.
• The vesting schedule based on both time and performance criteria could motivate the director to contribute to the company's long-term success.

Risks

• The performance-based vesting is contingent on the company's stock price reaching certain targets, which may not be achieved.
• The director's continued service is required for the options to vest, so any departure could impact the vesting schedule.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholders and incentivizing long-term growth.

Comparison to Industry Standards

• Stock option grants are a standard practice in the biotech industry to incentivize executives and align their interests with shareholders.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their compensation packages.
• The vesting schedules and performance criteria are generally tailored to the specific goals and circumstances of each company.

Stakeholder Impact

• The granting of stock options can positively impact shareholders by aligning the director's interests with increasing the company's value.
• Employees may be indirectly impacted as the director's performance could influence the company's overall success.

Key Dates

Keywords

stock options, director, Prime Medicine, PRME, beneficial ownership, Form 4, securities, Marrazzo, vesting